Bipolar Disorder Clinical Trial
Official title:
Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder
Pediatric Bipolar Disorder (BD) is uncommon in children. Its symptoms include periods of
manic behavior (being overly happy or giddy, feeling grandiose, feeling a decreased need for
sleep, having too much energy, moving more than usual, talking fast, having speeded-up
thoughts and other symptoms). Sometimes there also is depression (extreme feelings of sadness
or irritability, not taking pleasure in things, even ones that used to be enjoyable, feeling
worthless or guilty, sleeping too much or having trouble getting to or staying asleep,
feeling slowed down or restless, having wishes to be dead or suicidal ideas, and other
symptoms). Pediatric BD is often difficult to treat; children may respond only partially to
the medications now available or have too many side effects to tolerate them.
Riluzole is a medication that is thought to work on a brain chemical called glutamate that
may be involved in symptoms of depression and BD. Previous research studies have shown that
riluzole may help adults with BD who have depression and adults who have depression, anxiety
disorders, or obsessive-compulsive disorders. Riluzole may also be helpful for children with
obsessive-compulsive disorder. However, it has never been given to children with BD.
This study will evaluate the effectiveness of riluzole in 80 patients between 9 and 17 years
of age who have BD and symptoms of anxiety. Participants must have tried at least two other
medications that have not been effective.
The study will consist of four phases carried out over 4 to 5 months. Most children will be
inpatients at the Pediatric Behavioral Health Unit for at least part of the study.
In Phase 1, each patient will undergo blood and urine tests, and will gradually taper off his
or her medication. The duration of this phase depends on the medication that the patient was
receiving before starting the study.
In Phase 2, the patient will remain off all medication for 1 week. Throughout this time,
patients will be monitored carefully and medication will be restarted if needed.
In Phase 3, which lasts 8 weeks, patients will be assigned randomly to receive only riluzole
or only a placebo. Those who receive riluzole will have the dose adjusted as needed. Patients
and families will be informed of which drug they were on at the end of this phase. Patients
who improved on riluzole may continue to receive it from NIH for 1 month and will then be
prepared for discharge from the study. Patients who received placebo and improved, and those
who received riluzole but did not improve, will be treated with standard medications as
appropriate and prepared for discharge from the study.
Phase 4 is for patients who received placebo and did not improve. They will be given the
chance to try riluzole for 8 weeks and, if it is effective, continue it for an additional 4
weeks while they prepare to be discharged from the study.
Patients will not be able to receive riluzole at the National Institutes of Health after the
completion of the study. However, the child's doctor may be able to prescribe riluzole as an
off-label use.
Most patients will be admitted to the Pediatric Behavioral Health Unit at the National
Institutes of Health Clinical Center during the medication withdrawal part of the study
(Phases 1 and 2). From Phase 3 on, a patient may participate as an inpatient, outpatient, or
in day treatment, depending on what is in his or her best interests.
All participants in this study will be invited to also enroll in the National Institute of
Mental Health protocol 00-M-0198, The Phenomenology and Neurophysiology of Affective
Dysregulation In Children And Adolescents With Bipolar Disorder. Some research tests for that
protocol will be done during the medication-free period of this protocol.
OBJECTIVE: To test the efficacy of riluzole in youth with bipolar disorder
STUDY POPULATION: Youth, ages 9-17, with DSM-IV bipolar disorder, who have failed to respond
to two adequate trials of medication, one with an atypical antipsychotic medication, and the
second with either a mood stabilizing medication or a second atypical antipsychotic
medication.
DESIGN: Medication withdrawal, followed by a 15-day dose stabilization phase and a 6-week
double-blind, placebo-controlled treatment trial. The first two phases will be completed as
inpatients or in day treatment, while the third phase can be completed either in those
settings or as an outpatient. Individuals who received placebo will be offered an 8-week open
trial of riluzole followed by an additional 4 weeks if they respond, while those who received
riluzole in the placebo-controlled trial and wish to continue it will receive 4 weeks of open
treatment. Thus, all patients will have the opportunity to receive a total of 12 weeks of
riluzole treatment.
OUTCOME MEASURES: Clinical rating scales, including the Pediatric Anxiety Rating Scale and
the Clinical Global Improvement Scale
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT02855762 -
Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder
|
N/A | |
Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
Recruiting |
NCT05206747 -
Ottawa Sunglasses at Night for Mania Study
|
N/A | |
Completed |
NCT02513654 -
Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects
|
Phase 1 | |
Recruiting |
NCT06313918 -
Exercise Therapy in Mental Disorders-study
|
N/A | |
Completed |
NCT02304432 -
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
|
Early Phase 1 | |
Recruiting |
NCT06197048 -
Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder
|
N/A | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT02212041 -
Electronic Cigarettes in Smokers With Mental Illness
|
N/A | |
Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
Not yet recruiting |
NCT04432116 -
Time and Virtual Reality in Schizophrenia and Bipolar Disorder
|
N/A | |
Terminated |
NCT02893371 -
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
|
||
Completed |
NCT02970721 -
Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
|
||
Terminated |
NCT02909504 -
Gao NARASD Lithium Study
|
Phase 4 | |
Recruiting |
NCT02481245 -
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
|
Phase 2 | |
Recruiting |
NCT03088657 -
Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
|